Does PBYI pay a dividend?

The cached stock data on this page does not show a positive dividend yield for PBYI. Dividend status can change, so verify the latest company filings before relying on income assumptions.

What does PBYI stock do?

Commercial-stage biopharmaceutical company focused on oncology. Revenue is primarily generated through U.S. commercial sales of oral neratinib (NERLYNX) for HER2-positive breast cancer, supplemented by international licensing milestones and royalties from global distribution partners.

What is PBYI stock's price target?

This cached page does not contain a precise model fair value for PBYI.

The TradeMates model verdict for PBYI is HOLD with an investment score of 58/100. Treat this as a model signal to review, not a personal buy recommendation.

Is PBYI a good dividend stock?

PBYI is not presented as a dividend idea on this cached TradeMates page because no positive dividend yield is available in the cached data.

PBYI (PBYI) Stock Analysis

Q: Is PBYI stock a good investment?

The cached TradeMates AI model rates PBYI as HOLD with an investment score of 58/100. Puma Biotechnology combines solid short-term profitability ($41.7M FCF in 2025) with long-term revenue stagnation and insider selling, rendering the stock a Hold near 52-week highs. This is algorithmic model output, not personal investment advice.

Verdict: HOLD

Profitable commercial-stage oncology model with 8.3% FCF yield faces multi-year EPS declines and heavy insider selling.

Investment score: 58/100

Puma Biotechnology combines solid short-term profitability ($41.7M FCF in 2025) with long-term revenue stagnation and insider selling, rendering the stock a Hold near 52-week highs.

Peers

RGNX
ZURA
TECX
SCTX
ASMB

Peer	P/E	P/B	P/S	EV/EBITDA	ROIC %	Net margin %
RGNX	-2.04	5.68	2.29	-3.10	—	-1.13
ZURA	-3.77	2.74	0.00	-2.32	—	0.00
TECX	-5.59	2.16	0.00	-3.09	—	0.00
ASMB	44.58	1.51	6.49	6705.43	—	-0.00

View the full interactive analysis